SREBP-‐1c, ChREBPy LXR…
47
178.
Ross, S.E., Erickson, R.L., Gerin, I. y col. 2002. Microarray analyses during
adipogenesis: understanding the effects ofWnt signaling on adipogenesis and the roles of
liverXreceptor alpha inadipocytemetabolism.Mol Cell Biol 22, 5989-‐5999.
179.
Dalen, K.T., Ulven, S.M., Bamberg, K. y col. 2003. Expression of the insulin-‐
responsive glucose transporter GLUT4 in adipocytes is dependent on liver X receptor
alpha. JBiol Chem278, 48283-‐48291.
180.
Gerin, I., Dolinsky, V.W., Shackman, J.G. y col. 2005. LXRbeta is required for
adipocyte growth, glucose homeostasis, and beta cell function. J Biol Chem 280, 23024-‐
23031.
181.
Pettersson, A.M., Stenson, B.M., Lorente-‐Cebrián, S. y col. 2013. LXR is a negative
regulatorof glucoseuptake inhumanadipocytes. Diabetologia56, 2044-‐2054.
182.
Zitzer, H.,Wente,W., Brenner, M.B. y col. 2006. Sterol regulatory element-‐binding
protein1mediates liverX receptor-‐beta-‐induced increases in insulin secretionand insulin
messenger ribonucleicacid levels. Endocrinology147, 3898-‐3905.
183.
Choe, S.S., Choi, A.H., Lee, J.W. y col. 2007. Chronic activation of liver X receptor
induces beta-‐cell apoptosis through hyperactivation of lipogenesis: liver X receptor-‐
mediated lipotoxicity inpancreaticbeta-‐cells. Diabetes56, 1534-‐1543.
184.
López, J.M., Bennett, M.K., Sanchez, H.B. y col. 1996. Sterol regulation of acetyl
coenzyme A carboxylase: a mechanism for coordinate control of cellular lipid. Proc Natl
AcadSciUSA93, 1049-‐1053.
185.
Tabor, D.E., Kim, J.B., Spiegelman, B.M., Edwards, P.A., 1998. Transcriptional
activation of the stearoyl-‐CoA desaturase 2 gene by sterol regulatory element-‐binding
protein/adipocyte determination and differentiation factor 1. J Biol Chem 273, 22052-‐
22058.
186.
Joseph, S.B., Laffitte, B.A., Patel, P.H. y col. 2002. Direct and indirect mechanisms
for regulationof fatty acid synthase gene expressionby liver X receptors. J Biol Chem277,
11019-‐11025.
187.
Chisholm, J.W., Hong, J., Mills, S.A., Lawn, R.M., 2003. The LXR ligand T0901317
induces severe lipogenesis in thedb/dbdiabeticmouse. J LipidRes44, 2039-‐2048.
188.
Grefhorst, A., Elzinga, B.M., Voshol, P.J. y col. 2002. Stimulation of lipogenesis by
pharmacological activation of the liver X receptor leads to production of large,
triglyceride-‐richvery lowdensity lipoproteinparticles. JBiol Chem277, 34182-‐34190.
189.
Ducheix, S., Montagner, A., Polizzi, A. y col. 2013. Essential fatty acids deficiency
promotes lipogenic gene expression and hepatic steatosis through the liver X receptor. J
Hepatol 58, 984-‐992.
190.
Patel, R., Patel,M., Tsai, R. y col. 2011. LXRβ is required for glucocorticoid-‐induced
hyperglycemiaandhepatosteatosis inmice. J Clin Invest 121, 431-‐441.
191.
Ducheix, S., Montagner, A., Theodorou, V. y col. 2013. The liver X receptor: a
master regulator of the gut-‐liver axis and a target for non alcoholic fatty liver disease.
BiochemPharmacol 86, 96-‐105.
192.
Higuchi, N., Kato, M., Shundo, Y. y col. 2008. Liver X receptor in cooperationwith
SREBP-‐1c is a major lipid synthesis regulator in nonalcoholic fatty liver disease. Hepatol
Res38, 1122-‐1129.
193.
Zelcer, N., Tontonoz, P., 2006. Liver X receptors as integrators of metabolic and
inflammatorysignaling. J Clin Invest 116, 607-‐614.
194.
Hong, C., Tontonoz, P., 2008. Coordination of inflammation and metabolism by
PPARandLXRnuclear receptors. CurrOpinGenetDev18, 461-‐467.
195.
Jakobsson, T., Treuter, E., Gustafsson, J., Steffensen, K.R., 2012. Liver X receptor
biology and pharmacology: new pathways, challenges and opportunities. Trends
Pharmacol Sci 33, 394-‐404.
196.
Wang, Y.Y., Dahle, M.K., Agren, J. y col. 2006. Activation of the liver X receptor
protects against hepatic injury in endotoxemia by suppressing Kupffer cell activation.
Shock25, 141-‐146.
197.
Mallat, A., Lotersztajn, S., 2011. The liver X receptor in hepatic stellate cells: a
novel antifibrogenic target? JHepatol 55, 1452-‐1454.
198.
Beaven, S.W., Wroblewski, K., Wang, J. y col. 2011. Liver X receptor signaling is a
determinant of stellate cell activation and susceptibility to fibrotic liver disease.
Gastroenterology140, 1052-‐1062.
